University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study) : a multicentre, randomised, double-blind trial

Simple item page
dc.contributor.authorNorman, Jane Elizabeth
dc.contributor.authorMarlow, Neil
dc.contributor.authorMessow, Claudia-Martina
dc.contributor.authorShennan, Andrew
dc.contributor.authorBennett, Phillip R.
dc.contributor.authorThornton, Steven
dc.contributor.authorRobson, Stephen C.
dc.contributor.authorMcConnachie, Alex
dc.contributor.authorPetrou, Stavros
dc.contributor.authorSebire, Neil J.
dc.contributor.authorLavender, Tina
dc.contributor.authorWhyte, Sonia
dc.contributor.authorNorrie, John
dc.contributor.authorOPPTIMUM study group
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Evaluationen
dc.date.accessioned2016-06-20T12:40:02Z
dc.date.available2016-06-20T12:40:02Z
dc.date.issued2016-05
dc.descriptionAcknowledgments We thank the members of the Trial Steering and Data Monitoring Committee and all the people who helped in the conduct of the study (including the OPPTIMUM collaborative group and other clinicians listed in the appendix). We are grateful to Paul Piette (Besins Healthcare Corporate, Brussels, Belgium) and Besins Healthcare for their kind donation of active and placebo drug for use in the study, and to staff of the pharmacy and research and development departments of the participating hospitals. We are also grateful to the many people who helped in this study but who we have been unable to name, and in particular all the women (and their babies) who participated in OPPTIMUM. OPPTIMUM was funded by the Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute of Health Research (NIHR) partnership, award number G0700452, revised to 09/800/27. The EME Programme is funded by the MRC and NIHR, with contributions from the Chief Scientist Office in Scotland and National Institute for Social Care and Research in Wales. The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, National Health Service, NIHR, or the Department of Health. The funder had no involvement in data collection, analysis or interpretation, and no role in the writing of this manuscript or the decision to submit for publication.en
dc.description.statusPeer revieweden
dc.format.extent11
dc.format.extent226994
dc.identifier63639519
dc.identifier136ec661-6deb-4c9d-8dc9-3f728f573959
dc.identifier26921136
dc.identifier84959111461
dc.identifier.citationNorman, J E, Marlow, N, Messow, C-M, Shennan, A, Bennett, P R, Thornton, S, Robson, S C, McConnachie, A, Petrou, S, Sebire, N J, Lavender, T, Whyte, S, Norrie, J & OPPTIMUM study group 2016, 'Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study) : a multicentre, randomised, double-blind trial', The Lancet, vol. 387, no. 10033, pp. 2106-2116. https://doi.org/10.1016/S0140-6736(16)00350-0en
dc.identifier.doi10.1016/S0140-6736(16)00350-0
dc.identifier.iss10033en
dc.identifier.issn0140-6736
dc.identifier.urihttp://hdl.handle.net/2164/6135
dc.identifier.vol387en
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.subjectR Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectG0700452en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject09/800/27en
dc.subjectChief Scientist Office (CSO)en
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleVaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study) : a multicentre, randomised, double-blind trialen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
1_s2.0_S0140673616003500_main.pdf
Size:
221.67 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
8.29 KB
Format:
Plain Text
Description:
Download

Collections

All research
Applied Health Sciences research
University Office research